Research Article
Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma
Table 1
Baseline characteristics of HCC patients for the entire study.
| Variable | | N = 79 | n | % |
| Gender | Male | 74 | 93.7 | Female | 5 | 6.3 |
| Age (years) | >50 | 47 | 59.5 | ≤50 | 32 | 40.5 |
| CTC count | >1 | 42 | 53.2 | ≤1 | 37 | 46.8 |
| Tumor number | >3 | 15 | 19.0 | ≤3 | 64 | 81.0 |
| Tumor diameter (cm) | >3 | 31 | 39.2 | ≤3 | 48 | 60.8 |
| PVT | Yes | 16 | 20.3 | No | 63 | 79.7 |
| MVI | Yes | 15 | 19.0 | No | 64 | 81.0 |
| Edmonson stage | I-II | 48 | 60.8 | III-IV | 31 | 39.2 |
| Liver cirrhosis | Yes | 73 | 92.4 | No | 6 | 7.6 |
| Milan criteria | Yes | 46 | 58.2 | No | 33 | 41.7 |
| UCSF criteria | Yes | 51 | 64.6 | No | 28 | 35.4 |
| HBsAg (+) | Yes | 65 | 82.3 | No | 14 | 17.7 |
| AFP (ng/ml) | >400 | 20 | 25.3 | ≤400 | 59 | 74.7 |
| TNM stage | I | 10 | 12.7 | II | 23 | 29.1 | III-IV | 46 | 58.2 |
| Pretransplantation treatment | Yes | 51 | 64.6 | No | 28 | 35.4 |
| RFA only | Yes | 18 | 22.8 | No | 61 | 77.2 |
| Recurrence | Yes | 20 | 25.3 | No | 59 | 74.7 |
|
|
AFP: alpha-fetoprotein; CTC: circulating tumor cells; HBsAg: hepatitis B surface antigen; HCC: hepatocellular carcinoma; MVI: microvascular invasions; PVT: portal vein thrombosis; RFA: radiofrequency ablation; UCSF: University of California San Francisco.
|